<DOC>
	<DOCNO>NCT02295865</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability JNJ-38518168 participant moderate severe plaque-type psoriasis ( common genetically determine , chronic , inflammatory skin disease characterize rounded erythematous , dry , scale patch ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Toreforant ( JNJ-38518168 ) Participants With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither researcher participant know treatment participant receiving ) , parallel-group , placebo-controlled ( inactive substance ; pretend treatment [ drug ] compare clinical trial drug test drug real effect ) study . The study consist Screening Phase ( maximum 42 day prior Week 0 ) , Treatment Phase ( Week 0-12 ) Follow-up Phase ( Week 16 ) . Participants randomly assign receive JNJ-38518168 ( 3 milligram [ mg ] 30 mg 60 mg ) placebo daily . The initial group participant randomize either JNJ-38518168 30 mg placebo . The dose assignment subsequent participant depend result 2 interim analysis . Efficacy primarily assess percentage participant achieve Psoriasis Area Severity Index ( PASI ) 75 response Week 12 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Participant must diagnosis plaquetype psoriasis ( without psoriatic arthritis [ PsA ] ) least 6 month first administration study drug Participant must Psoriasis Area Severity Index ( PASI ) Greater Than equal ( &gt; = ) 12 screen baseline Participant must Investigator 's Global Assessment ( IGA ) &gt; =3 screen baseline A woman childbearing potential must negative urine pregnancy test screen Week 0 A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control study 4 month receive last administration study drug . All men must also agree donate sperm study 4 month receive last administration study drug Participant history current sign symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Participant current malignancy history malignancy within 5 year screen ( exception nonmelanoma skin cancer adequately treat evidence recurrence least 3 month first study drug administration , cervical carcinoma situ treat evidence recurrence least 1 year first study drug administration ) Participant history lymphoproliferative disease , include lymphoma ; history monoclonal gammopathy undetermined significance ( MGUS ) ; sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy splenomegaly Participant history chronic recurrent infectious disease , include limited chronic renal infection , chronic chest infection ( eg , bronchiectasis ) , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , fungal infection ( mucocutaneous candidiasis ) , open , drain , infected skin wound ulcer Participant history infect joint prosthesis , receive antibiotic suspected infection joint prosthesis , prosthesis remove replace Participant ever receive previous biologic therapy psoriasis psoriatic arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Toreforant</keyword>
	<keyword>JNJ-38518168</keyword>
</DOC>